抗凝治疗对慢性阻塞性肺疾病患者血清TNF-α及白介素表达的影响

doi:10.3969/j.issn.1006-6233.2020.01.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1207 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study effect of TNF-α and interleukin(IL-18andIL-6)in patients with chronic obstructive pulmonary disease using anticoagulant drugs. Method: 94 patients were divided into two groups, 47 in each group. The conventional group used common therapy, and the anticoagulation group used anticoagulant drugs on the basis of the conventional group. Observe the following indicator changes. Results: The effective rate of COPD patients in the anticoagulation group was significantly higher than that in the conventional group(P＜0.05). There was no difference between the two groups before treatment (P > 0.05). After treatment, the levels of TNF - α, IL-18 and IL-6 in the two groups were significantly lower than those in the anticoagulant group (P < 0.05). The patients in the routine group and anticoagulant group had different degrees of ecchymosis, increased platelet count and other symptoms. The single ecchymosis disappeared by itself, and the platelet and coagulation time returned to the normal level. There was no difference between the two groups (P > 0.05). Conclusion: The expression of TNF - α, IL-18 and IL-6 in the serum of patients with COPD can be significantly inhibited by antitussive and expectorant drugs combined with anticoagulant therapy. The clinical effect of COPD is obviously improved, which is worth popularizing.

Key words： COPD TNF-α IL-18 IL-6 Anticoagulant therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Qingyun
	LI Jiwei
	LIAO Dongchen
	et al

Cite this article:

CHEN Qingyun,LI Jiwei,LIAO Dongchen, et al. Effect of Anticoagulant Therapy on Serum TNF-α and Interleukin Expression in Patients with Chronic Obstructive Pulmonary Disease[J]. HeBei Med, 2020, 26(1): 93-96.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.01.022 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I1/93

[1] 申永春,文富强.2018年慢性阻塞性肺疾病全球创议更新解读[J].中国实用内科杂志,2018,38(5):65~67.
[2] 史燕,方英,李云娜,等.慢性阻塞性肺疾病合并肺部真菌感染的危险因素分析及护理对策[J].中华全科医学,2018,33(11):55~58.
[3] Kourlaba G, Hillas G, Vassilakopoulos T, et al. The economic burden of chronic obstructive pulmonary disease in greece[J]. Applied Health Economics and Health Policy, 2019, 17(1):111~121.
[4] 陈颖,石赟,陈燕蓉,等.稳定期慢性阻塞性肺疾病患者外周血T淋巴细胞活化标志物表达水平的研究[J].临床和实验医学杂志,2018,4(12):33~35.
[5] 喻益勇.参麦注射液联合BiBap无创呼吸机对慢性阻塞性肺疾病并Ⅱ型呼吸衰竭患者血氧浓度及高凝血状态的影响[J].血栓与止血学,2017,23(5):817.
[6] 邢春蕊,陈应奇,李乐雯.等噻托溴铵联合沙美特罗及丙酸氟替卡松对老年稳定期慢性阻塞性肺疾病患者血清炎性因子水平的影响[J].中国药业,2018,27(8):36~39.
[7] 梁杨丽,毛兵.稳定期慢性阻塞性肺疾病患者血浆及诱导痰中炎性因子水平变化[J].中华实用诊断与治疗杂志,2018,32(11):53~56.
[8] 赵丽格,闫佳强,李富东,等.COPD稳定期患者以噻托溴铵联合舒利迭治疗的效果分析[J].国际医药卫生导报,2018,24(12):1849.
[9] 唐凤敏,徐红冰.使用华法林抗凝的肺栓塞患者出血与止血治疗矛盾的处理方法[J].中国药房,2016,27(20):2858~2861.
[10] 宋淑范,辛平.炎症细胞因子IL-1β,IL-6,TNF-α,IL-18对慢性阻塞性肺疾病模型小鼠肺癌生长及转移的影响[J].临床与病理杂志,2017,37(11):23~25.
[11] 梁章荣,李旷怡,陈景利,等.肿瘤坏死因子α和白介素8对慢性阻塞性肺疾病急性加重期的诊断价值[J].实用心脑肺血管病杂志,2017,9(4):131~133.
[12] 文倩,陈春玲,杨淑群,等.华法林抗凝治疗慢性阻塞性肺疾病急性加重期患者的可行性及安全性观察[J].海南医学,2018,33(220):330~345.
[13] 王虹娟,刘鑫,曹永宏,等慢性阻塞性肺疾病急性加重期患者炎性介质与凝血状态相关性研究[J].国际检验医学杂志,2017,3(12):77~81.